These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 9436721)

  • 1. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
    Poewe W; Deuschl G; Nebe A; Feifel E; Wissel J; Benecke R; Kessler KR; Ceballos-Baumann AO; Ohly A; Oertel W; Künig G
    J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):13-7. PubMed ID: 9436721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
    Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
    J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study.
    Wissel J; Kanovsky P; Ruzicka E; Bares M; Hortova H; Streitova H; Jech R; Roth J; Brenneis C; Müller J; Schnider P; Auff E; Richardson A; Poewe W
    J Neurol; 2001 Dec; 248(12):1073-8. PubMed ID: 12013585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type A therapy for cervical dystonia.
    Rodrigues FB; Duarte GS; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003633. PubMed ID: 33180963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
    Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
    Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
    Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study.
    Hyman N; Barnes M; Bhakta B; Cozens A; Bakheit M; Kreczy-Kleedorfer B; Poewe W; Wissel J; Bain P; Glickman S; Sayer A; Richardson A; Dott C
    J Neurol Neurosurg Psychiatry; 2000 Jun; 68(6):707-12. PubMed ID: 10811692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A therapy for cervical dystonia.
    Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
    Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
    Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
    Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
    Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
    Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
    Rystedt A; Nyholm D; Naver H
    Clin Neuropharmacol; 2012; 35(6):278-82. PubMed ID: 23123690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
    Laubis-Herrmann U; Fries K; Topka H
    Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
    Hauser RA; Truong D; Hubble J; Coleman C; Beffy JL; Chang S; Picaut P
    J Neural Transm (Vienna); 2013 Feb; 120(2):299-307. PubMed ID: 22878514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke.
    Pittock SJ; Moore AP; Hardiman O; Ehler E; Kovac M; Bojakowski J; Al Khawaja I; Brozman M; Kanovský P; Skorometz A; Slawek J; Reichel G; Stenner A; Timerbaeva S; Stelmasiak Z; Zifko UA; Bhakta B; Coxon E
    Cerebrovasc Dis; 2003; 15(4):289-300. PubMed ID: 12686794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.